A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer

[1]  F. Marofi,et al.  Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction , 2022, Cancer cell international.

[2]  Jing Jiang,et al.  Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy , 2022, Frontiers in Oncology.

[3]  Shengli Liu,et al.  Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer , 2022, Frontiers in Immunology.

[4]  L. Zitvogel,et al.  Immunogenic cell stress and death , 2022, Nature Immunology.

[5]  M. Rose,et al.  Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer , 2021, International journal of molecular sciences.

[6]  N. Agarwal,et al.  Advances in bladder cancer biology and therapy , 2020, Nature Reviews Cancer.

[7]  A. Lenis,et al.  Bladder Cancer: A Review. , 2020, JAMA.

[8]  W. Oh,et al.  Treatment of muscle‐invasive and advanced bladder cancer in 2020 , 2020, CA: a cancer journal for clinicians.

[9]  Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for immunotherapy of cancer.

[10]  L. Kiemeney,et al.  The global burden of urinary bladder cancer: an update , 2019, World Journal of Urology.

[11]  C. Van Waes,et al.  Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. , 2019, Oral oncology.

[12]  T. Powles,et al.  Molecular and histopathology directed therapy for advanced bladder cancer , 2019, Nature Reviews Urology.

[13]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  N. Schultz,et al.  NEXT GENERATION SEQUENCING OF NON‐MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS: PD48‐11 , 2017, European urology.

[15]  Muhammad S. Khan,et al.  Landmarks in the treatment of muscle-invasive bladder cancer , 2017, Nature Reviews Urology.

[16]  T. Ørntoft,et al.  Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. , 2017, European urology.

[17]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[18]  L. Zitvogel,et al.  Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Steven L. Chang,et al.  Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. , 2014, European urology.

[20]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[21]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.